CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PRKAR2A (ImmuneEditome ID:5576)

1. Gene summary of enriched editing regions for PRKAR2A

check button Gene summary
Gene informationGene symbol

PRKAR2A

Gene ID

5576

GeneSynonymsPKR2|PRKAR2
GeneCytomap

3p21.31

GeneTypeprotein-coding
GeneDescriptioncAMP-dependent protein kinase type II-alpha regulatory subunit|cAMP-dependent protein kinase regulatory subunit RII alpha|protein kinase A, RII-alpha subunit|protein kinase, cAMP-dependent, regulatory subunit type II alpha
GeneModificationdate20230518
UniprotIDP13861;A0A024R2W3;C9J830;A0A0S2Z472
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:48749537-48750463:-ENST00000265563.11ENSG00000114302.14PRKAR2AUTR3AluSp,AluSx3,AluJrchr3:48749537-48750463:-.alignment
chr3:48749537-48750463:-ENST00000296446.11ENSG00000114302.14PRKAR2AUTR3AluSp,AluSx3,AluJrchr3:48749537-48750463:-.alignment
chr3:48840242-48841068:-ENST00000265563.11ENSG00000114302.14PRKAR2AintronicAluY,L1MB4,AluSq2,AluSxchr3:48840242-48841068:-.alignment
chr3:48840242-48841068:-ENST00000296446.11ENSG00000114302.14PRKAR2AintronicAluY,L1MB4,AluSq2,AluSxchr3:48840242-48841068:-.alignment
chr3:48840242-48841068:-ENST00000419216.1ENSG00000114302.14PRKAR2AintronicAluY,L1MB4,AluSq2,AluSxchr3:48840242-48841068:-.alignment
chr3:48840242-48841068:-ENST00000454963.4ENSG00000114302.14PRKAR2AintronicAluY,L1MB4,AluSq2,AluSxchr3:48840242-48841068:-.alignment


Top

2. Tumor-specific enriched editing regions for PRKAR2A


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr3:48749537-48750463:-BRCAEER2.9233e-17image
ENSG00000114302.14,PRKAR2ABRCAEAG7.3285e-15image
chr3:48749537-48750463:-COADEER5.3226e-17image
ENSG00000114302.14,PRKAR2ACOADEAG1.0931e-16image
chr3:48749537-48750463:-HNSCEER4.3961e-12image
ENSG00000114302.14,PRKAR2AHNSCEAG1.5599e-11image
chr3:48749537-48750463:-KIRCEER1.3216e-18image
ENSG00000114302.14,PRKAR2AKIRCEAG1.2609e-17image
chr3:48749537-48750463:-KIRPEER5.1031e-05image
ENSG00000114302.14,PRKAR2AKIRPEAG7.8650e-05image
chr3:48749537-48750463:-LUADEER9.6726e-04image
ENSG00000114302.14,PRKAR2ALUADEAG1.0786e-02image
chr3:48749537-48750463:-LUSCEER1.1461e-09image
ENSG00000114302.14,PRKAR2ALUSCEAG1.0922e-08image
chr3:48749537-48750463:-STADEER2.3687e-02image
chr3:48749537-48750463:-THCAEER1.7378e-08image
ENSG00000114302.14,PRKAR2ATHCAEAG5.3914e-08image
ENSG00000114302.14,PRKAR2AUCECEAG4.4267e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr3:48749537-48750463:-BRCAPathEER8.5427e-033.2272e-020.0665image
chr3:48749537-48750463:-KIRCPathEER2.5844e-022.9669e-020.1008image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000114302.14,PRKAR2ALAMLEAG3.6386e-025.2631e-033.3538e+01image

Top

3. Enriched editing regions and immune related genes for PRKAR2A


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:48749537-48750463:-KIRCEERENSG00000160007,ARHGAP35-0.35366.9178e-091.0866e-14-0.4033imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr3:48749537-48750463:-KIRCEERENSG00000107185,RGP1-0.33261.8640e-081.2552e-14-0.4024imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr3:48749537-48750463:-KIRCEERENSG00000130723,PRRC2B-0.31831.6988e-071.5875e-14-0.4010imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2PRRC2BT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:48749537-48750463:-KIRCEERENSG00000273271,AP000254.80.32692.5179e-075.9612e-160.4204imageNELAVL1;IGF2BP2;NOP58;SRSF1NAT_cells_follicular_helperGSVA_HALLMARK_HEME_METABOLISM
chr3:48749537-48750463:-KIRCEERENSG00000272112,CTB-113P19.50.31075.4279e-073.9189e-190.4598imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr3:48749537-48750463:-KIRCEERENSG00000123444,KBTBD4-0.27142.5304e-051.6256e-14-0.4008imageNCSTF2T;DDX54;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;IGF2BP2;LIN28B;NOP56;NOP58;SRSF1;SRSF3;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr3:48749537-48750463:-KIRPEERENSG00000174021,GNG50.40402.2472e-072.5192e-180.5448imageNCSTF2T;DDX54;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE
chr3:48749537-48750463:-KIRPEERENSG00000176986,SEC24C-0.36054.3254e-062.0165e-10-0.4128imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:48749537-48750463:-KIRPEERENSG00000224877,C17orf890.34881.5518e-055.6241e-110.4242imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr3:48749537-48750463:-KIRPEERENSG00000250222,CTC-338M12.50.34051.6173e-051.7408e-140.4877imageNCSTF2T;ELAVL1;FAM120A;FBL;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NAMacrophages_M1GSVA_HALLMARK_HEDGEHOG_SIGNALING
chr3:48749537-48750463:-KIRCEERENSG00000160007,ARHGAP35-0.35366.9178e-091.0866e-14-0.4033imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr3:48749537-48750463:-KIRCEERENSG00000107185,RGP1-0.33261.8640e-081.2552e-14-0.4024imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr3:48749537-48750463:-KIRCEERENSG00000130723,PRRC2B-0.31831.6988e-071.5875e-14-0.4010imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2PRRC2BT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:48749537-48750463:-KIRCEERENSG00000273271,AP000254.80.32692.5179e-075.9612e-160.4204imageNELAVL1;IGF2BP2;NOP58;SRSF1NAT_cells_follicular_helperGSVA_HALLMARK_HEME_METABOLISM
chr3:48749537-48750463:-KIRCEERENSG00000272112,CTB-113P19.50.31075.4279e-073.9189e-190.4598imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr3:48749537-48750463:-KIRCEERENSG00000123444,KBTBD4-0.27142.5304e-051.6256e-14-0.4008imageNCSTF2T;DDX54;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;IGF2BP2;LIN28B;NOP56;NOP58;SRSF1;SRSF3;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr3:48749537-48750463:-KIRPEERENSG00000174021,GNG50.40402.2472e-072.5192e-180.5448imageNCSTF2T;DDX54;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE
chr3:48749537-48750463:-KIRPEERENSG00000176986,SEC24C-0.36054.3254e-062.0165e-10-0.4128imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:48749537-48750463:-KIRPEERENSG00000224877,C17orf890.34881.5518e-055.6241e-110.4242imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr3:48749537-48750463:-KIRPEERENSG00000250222,CTC-338M12.50.34051.6173e-051.7408e-140.4877imageNCSTF2T;ELAVL1;FAM120A;FBL;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NAMacrophages_M1GSVA_HALLMARK_HEDGEHOG_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for PRKAR2A


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000114302.14,PRKAR2A
COADEAGIRENSG00000105339.6chr8141173504:141176761:141178066:1411781960.19304.1550e-022.9985e-110.4398imageNACIN1;ADAR;ALYREF;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;RNF219;SF3A3;SLTM;SMNDC1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIAL1;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184NANeutrophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
ENSG00000114302.14,PRKAR2A
COADEAGIRENSG00000134255.9chr1111174878:111182318:111182798:1111829570.23172.7250e-025.3180e-130.4206imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZFP36;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000114302.14,PRKAR2A
COADEAGIRENSG00000131375.5chr315240753:15242253:15245525:152456710.21604.1794e-021.3962e-140.4479imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000114302.14,PRKAR2A
COADEAGIRENSG00000116977.14chr1236538878:236539089:236540563:2365406830.25867.1141e-032.6536e-140.4400imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAGLGALS8EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr3:48749537-48750463:-
COADEERIRENSG00000060237.12chr12879572:880999:881691:8817890.20421.2644e-022.2433e-130.4937imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2WNK1EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000114302.14,PRKAR2A
COADEAGIRENSG00000132694.14chr1156945018:156945197:156946044:1569461620.21914.1863e-025.4846e-120.4041imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184ARHGEF11EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr3:48749537-48750463:-
COADEERIRENSG00000090316.11chr41336836:1336994:1338421:13386170.23022.3782e-021.8964e-120.4100imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2MAEADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000114302.14,PRKAR2A
COADEAGIRENSG00000187742.10chr989332587:89332986:89334521:893347300.21763.4514e-021.9968e-130.4404imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr3:48749537-48750463:-
COADEERIRENSG00000153922.6chr598858963:98859015:98859971:988600680.24241.3330e-023.6149e-130.4227imageNCSTF2T;DDX54;DHX9;ELAVL1;FAM120A;FBL;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;LIN28B;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TARDBP;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000114302.14,PRKAR2A
COADEAGIRENSG00000083896.8chr468318518:68320205:68321371:683229150.21772.7827e-023.2221e-110.4067imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF3A;EIF3B;EIF3D;EIF3G;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZFP36;ZNF184NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

5. Enriched editing regions and immune infiltration for PRKAR2A


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000114302.14,PRKAR2ABLCAEAGNK_cells_activated2.3324e-020.1296image
chr3:48749537-48750463:-BRCAEERT_cells_regulatory_(Tregs)2.3522e-050.1306image
ENSG00000114302.14,PRKAR2ABRCAEAGT_cells_regulatory_(Tregs)7.8082e-050.1220image
chr3:48749537-48750463:-CESCEERMonocytes5.7734e-030.1748image
ENSG00000114302.14,PRKAR2ACESCEAGMonocytes2.7347e-030.1880image
chr3:48749537-48750463:-CHOLEERDendritic_cells_resting1.5493e-020.5332image
ENSG00000114302.14,PRKAR2ACHOLEAGDendritic_cells_resting1.7665e-020.5120image
chr3:48749537-48750463:-COADEERNeutrophils5.2934e-030.1686image
ENSG00000114302.14,PRKAR2ACOADEAGNeutrophils1.4825e-030.1918image
ENSG00000114302.14,PRKAR2ADLBCEAGT_cells_gamma_delta1.3229e-02-0.4269image
chr3:48749537-48750463:-GBMEERMacrophages_M09.5979e-04-0.2570image
ENSG00000114302.14,PRKAR2AGBMEAGMacrophages_M01.2560e-03-0.2513image
chr3:48749537-48750463:-HNSCEERT_cells_follicular_helper1.6630e-02-0.1123image
ENSG00000114302.14,PRKAR2AHNSCEAGT_cells_follicular_helper3.1844e-03-0.1377image
ENSG00000114302.14,PRKAR2AKICHEAGEosinophils3.2067e-020.2869image
chr3:48749537-48750463:-KIRCEERT_cells_regulatory_(Tregs)9.6850e-060.2377image
ENSG00000114302.14,PRKAR2AKIRCEAGT_cells_follicular_helper5.9064e-040.1849image
chr3:48749537-48750463:-KIRPEERNK_cells_resting1.3014e-020.1676image
ENSG00000114302.14,PRKAR2AKIRPEAGNK_cells_resting1.0760e-020.1720image
chr3:48749537-48750463:-LAMLEERT_cells_regulatory_(Tregs)2.4383e-030.3192image
ENSG00000114302.14,PRKAR2ALAMLEAGT_cells_regulatory_(Tregs)1.1634e-020.2592image
chr3:48749537-48750463:-LGGEERB_cells_memory7.0299e-030.1215image
ENSG00000114302.14,PRKAR2ALGGEAGB_cells_memory4.5904e-030.1277image
chr3:48749537-48750463:-LIHCEERPlasma_cells4.4722e-020.1227image
chr3:48749537-48750463:-LUADEERT_cells_gamma_delta1.2022e-020.1150image
ENSG00000114302.14,PRKAR2ALUADEAGT_cells_gamma_delta8.4550e-030.1201image
chr3:48749537-48750463:-LUSCEERMacrophages_M22.0300e-03-0.1424image
ENSG00000114302.14,PRKAR2ALUSCEAGB_cells_memory4.5989e-030.1306image
chr3:48749537-48750463:-MESOEERT_cells_regulatory_(Tregs)2.0306e-020.2990image
ENSG00000114302.14,PRKAR2AMESOEAGMast_cells_resting2.8789e-020.2824image
chr3:48749537-48750463:-OVEERNK_cells_activated2.9207e-030.1739image
ENSG00000114302.14,PRKAR2AOVEAGNK_cells_activated2.0824e-030.1798image
chr3:48749537-48750463:-PAADEERMacrophages_M23.4977e-03-0.2332image
ENSG00000114302.14,PRKAR2APAADEAGMacrophages_M26.8067e-03-0.2158image
chr3:48749537-48750463:-PCPGEERT_cells_gamma_delta3.9759e-030.2549image
ENSG00000114302.14,PRKAR2APCPGEAGT_cells_gamma_delta1.8691e-030.2724image
chr3:48749537-48750463:-PRADEERPlasma_cells5.4801e-03-0.1288image
ENSG00000114302.14,PRKAR2APRADEAGT_cells_regulatory_(Tregs)7.1884e-030.1240image
chr3:48749537-48750463:-READEERPlasma_cells4.6432e-020.2082image
chr3:48749537-48750463:-SKCMEERNK_cells_activated3.6786e-050.1974image
ENSG00000114302.14,PRKAR2ASKCMEAGNK_cells_activated4.5339e-050.1949image
chr3:48749537-48750463:-STADEERNK_cells_resting6.5183e-040.1764image
chr3:48840242-48841068:-STADEERT_cells_follicular_helper1.1754e-020.4776image
ENSG00000114302.14,PRKAR2ASTADEAGNK_cells_resting1.1157e-030.1688image
chr3:48749537-48750463:-TGCTEERT_cells_CD82.6980e-020.2036image
chr3:48749537-48750463:-THCAEEREosinophils4.1038e-02-0.0956image
ENSG00000114302.14,PRKAR2ATHCAEAGEosinophils2.1026e-02-0.1079image
chr3:48749537-48750463:-THYMEERDendritic_cells_activated1.1117e-020.3751image
ENSG00000114302.14,PRKAR2ATHYMEAGDendritic_cells_activated7.2647e-030.3907image
chr3:48749537-48750463:-UCECEERDendritic_cells_activated2.8031e-020.1942image
ENSG00000114302.14,PRKAR2AUCECEAGMast_cells_activated2.5756e-020.1919image
ENSG00000114302.14,PRKAR2AUVMEAGB_cells_memory1.7060e-020.3540image


Top

6. Enriched editing regions and immune gene sets for PRKAR2A


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr3:48749537-48750463:-BRCAEER8.1577e-050.12181.3634e-020.07645.1191e-030.08674.2487e-02-0.0629image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000114302.14,PRKAR2AACCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.0886e-02-0.3537image
chr3:48749537-48750463:-ACCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.2251e-02-0.3483image
ENSG00000114302.14,PRKAR2ABLCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.6933e-02-0.1265image
chr3:48749537-48750463:-BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.8256e-020.1351image
chr3:48749537-48750463:-BRCAGSVA_HALLMARK_UV_RESPONSE_DNEER3.8384e-21-0.2867image
ENSG00000114302.14,PRKAR2ABRCAGSVA_HALLMARK_UV_RESPONSE_DNEAG6.6372e-19-0.2702image
chr3:48749537-48750463:-CESCGSVA_HALLMARK_G2M_CHECKPOINTEER2.1970e-05-0.2660image
ENSG00000114302.14,PRKAR2ACESCGSVA_HALLMARK_G2M_CHECKPOINTEAG9.1125e-05-0.2440image
ENSG00000114302.14,PRKAR2ACHOLGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4485e-020.5252image
chr3:48749537-48750463:-CHOLGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0201e-020.5602image
ENSG00000114302.14,PRKAR2ACOADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG3.8349e-07-0.3020image
chr3:48749537-48750463:-COADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.0007e-06-0.2915image
ENSG00000114302.14,PRKAR2ADLBCGSVA_HALLMARK_G2M_CHECKPOINTEAG5.0349e-030.4767image
chr3:48749537-48750463:-ESCAGSVA_HALLMARK_MYC_TARGETS_V2EER3.8593e-030.2265image
ENSG00000114302.14,PRKAR2AESCAGSVA_HALLMARK_MYC_TARGETS_V2EAG2.7891e-030.2342image
chr3:48749537-48750463:-GBMGSVA_HALLMARK_MITOTIC_SPINDLEEER3.5177e-03-0.2280image
ENSG00000114302.14,PRKAR2AGBMGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.9604e-03-0.2252image
chr3:48749537-48750463:-HNSCGSVA_HALLMARK_UV_RESPONSE_DNEER1.8610e-07-0.2417image
ENSG00000114302.14,PRKAR2AHNSCGSVA_HALLMARK_UV_RESPONSE_DNEAG1.2574e-06-0.2244image
ENSG00000114302.14,PRKAR2AKICHGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.8872e-02-0.3129image
chr3:48749537-48750463:-KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER1.7046e-07-0.2794image
ENSG00000114302.14,PRKAR2AKIRCGSVA_HALLMARK_HEME_METABOLISMEAG3.4469e-06-0.2480image
ENSG00000114302.14,PRKAR2AKIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.5559e-04-0.2447image
chr3:48749537-48750463:-KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER1.2642e-04-0.2562image
chr3:48749537-48750463:-LAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.2280e-030.3391image
ENSG00000114302.14,PRKAR2ALAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.4581e-030.3088image
ENSG00000114302.14,PRKAR2ALGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.8152e-14-0.3366image
chr3:48749537-48750463:-LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER2.3546e-14-0.3352image
chr3:48749537-48750463:-LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER9.6935e-030.1578image
ENSG00000114302.14,PRKAR2ALUADGSVA_HALLMARK_DNA_REPAIREAG2.6800e-030.1368image
chr3:48749537-48750463:-LUADGSVA_HALLMARK_E2F_TARGETSEER2.7373e-030.1370image
chr3:48749537-48750463:-LUSCGSVA_HALLMARK_HEME_METABOLISMEER4.2031e-07-0.2316image
ENSG00000114302.14,PRKAR2ALUSCGSVA_HALLMARK_HEME_METABOLISMEAG3.0820e-06-0.2135image
chr3:48749537-48750463:-OVGSVA_HALLMARK_DNA_REPAIREER2.9093e-020.1280image
ENSG00000114302.14,PRKAR2AOVGSVA_HALLMARK_ANGIOGENESISEAG3.5537e-02-0.1233image
chr3:48749537-48750463:-PAADGSVA_HALLMARK_SPERMATOGENESISEER8.3348e-05-0.3107image
ENSG00000114302.14,PRKAR2APAADGSVA_HALLMARK_SPERMATOGENESISEAG1.3662e-04-0.3007image
ENSG00000114302.14,PRKAR2APCPGGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.2550e-02-0.2201image
chr3:48749537-48750463:-PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER5.3032e-03-0.2470image
chr3:48749537-48750463:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER3.9516e-07-0.2328image
ENSG00000114302.14,PRKAR2APRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.6734e-09-0.2637image
chr3:48749537-48750463:-READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.9825e-040.3616image
ENSG00000114302.14,PRKAR2AREADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9231e-030.3176image
ENSG00000114302.14,PRKAR2ASARCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG3.2461e-03-0.2003image
chr3:48749537-48750463:-SARCGSVA_HALLMARK_UV_RESPONSE_DNEER7.2780e-04-0.2303image
ENSG00000114302.14,PRKAR2ASKCMGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0807e-06-0.2321image
chr3:48749537-48750463:-SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.4532e-08-0.2687image
chr3:48840242-48841068:-STADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER4.7616e-020.3846image
chr3:48749537-48750463:-TGCTGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.1834e-020.2310image
ENSG00000114302.14,PRKAR2ATGCTGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG1.3334e-020.2254image
chr3:48749537-48750463:-THCAGSVA_HALLMARK_COAGULATIONEER1.3081e-040.1780image
ENSG00000114302.14,PRKAR2ATHCAGSVA_HALLMARK_COAGULATIONEAG4.3320e-040.1640image
ENSG00000114302.14,PRKAR2ATHYMGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG3.9897e-020.3041image
chr3:48749537-48750463:-THYMGSVA_HALLMARK_APOPTOSISEER1.0934e-020.3759image
chr3:48749537-48750463:-UCECGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.7565e-02-0.1840image
chr3:48749537-48750463:-UCSGSVA_HALLMARK_DNA_REPAIREER1.7893e-030.4626image
ENSG00000114302.14,PRKAR2AUCSGSVA_HALLMARK_DNA_REPAIREAG1.9755e-030.4587image
ENSG00000114302.14,PRKAR2AUVMGSVA_HALLMARK_SPERMATOGENESISEAG7.3408e-03-0.3944image


Top

7. Enriched editing regions and drugs for PRKAR2A


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr3:48749537-48750463:-ACCLFM.A13EER2.0981e-02-0.3225image
ENSG00000114302.14,PRKAR2AACCLFM.A13EAG1.8963e-02-0.3275image
chr3:48749537-48750463:-BLCACGP.082996EER3.1274e-03-0.1687image
ENSG00000114302.14,PRKAR2ABLCAErlotinibEAG1.9224e-03-0.1766image
chr3:48749537-48750463:-BRCAGW843682XEER1.9792e-10-0.1955image
ENSG00000114302.14,PRKAR2ABRCAGW843682XEAG1.5970e-11-0.2066image
chr3:48749537-48750463:-CESCCytarabineEER1.1731e-020.1598image
ENSG00000114302.14,PRKAR2ACESCAS601245EAG3.2129e-02-0.1350image
chr3:48749537-48750463:-COADCCT007093EER3.4682e-07-0.3031image
ENSG00000114302.14,PRKAR2ACOADCCT007093EAG3.2287e-08-0.3274image
ENSG00000114302.14,PRKAR2ADLBCBIBW2992EAG4.0091e-03-0.4875image
ENSG00000114302.14,PRKAR2AESCAGDC0941EAG2.0498e-020.1825image
chr3:48749537-48750463:-ESCABMS.708163EER2.5987e-020.1755image
chr3:48749537-48750463:-GBMBIBW2992EER2.7241e-03-0.2340image
ENSG00000114302.14,PRKAR2AGBMBIBW2992EAG4.4239e-03-0.2225image
chr3:48749537-48750463:-HNSCBAY.61.3606EER1.8044e-050.1998image
ENSG00000114302.14,PRKAR2AHNSCBAY.61.3606EAG5.6959e-050.1871image
ENSG00000114302.14,PRKAR2AKICHA.443654EAG1.0922e-020.3377image
chr3:48749537-48750463:-KIRCFH535EER2.6139e-070.2753image
ENSG00000114302.14,PRKAR2AKIRCFH535EAG5.4673e-070.2669image
chr3:48749537-48750463:-KIRPAZD6482EER7.2397e-040.2267image
ENSG00000114302.14,PRKAR2AKIRPAZD6482EAG5.6271e-040.2312image
chr3:48749537-48750463:-LAMLAUY922EER5.3376e-04-0.3618image
ENSG00000114302.14,PRKAR2ALAMLJNK.9LEAG3.2739e-03-0.3003image
ENSG00000114302.14,PRKAR2ALGGBX.795EAG3.0687e-060.2088image
chr3:48749537-48750463:-LGGBX.795EER4.1822e-060.2060image
chr3:48749537-48750463:-LIHCA.770041EER1.7982e-03-0.1934image
ENSG00000114302.14,PRKAR2ALIHCA.770041EAG3.8212e-02-0.1281image
chr3:48749537-48750463:-LUADJNK.Inhibitor.VIIIEER2.0104e-03-0.1412image
ENSG00000114302.14,PRKAR2ALUADFH535EAG6.2495e-040.1556image
ENSG00000114302.14,PRKAR2ALUSCABT.263EAG7.3751e-030.1236image
chr3:48749537-48750463:-LUSCABT.888EER6.6765e-03-0.1254image
chr3:48749537-48750463:-MESOErlotinibEER1.3545e-03-0.4044image
ENSG00000114302.14,PRKAR2AMESOErlotinibEAG8.7915e-04-0.4184image
ENSG00000114302.14,PRKAR2AOVEmbelinEAG1.1250e-020.1484image
chr3:48749537-48750463:-OVEmbelinEER4.1036e-030.1678image
chr3:48749537-48750463:-PAADAZD6244EER4.0616e-04-0.2806image
ENSG00000114302.14,PRKAR2APAADAZD6244EAG6.1652e-04-0.2712image
ENSG00000114302.14,PRKAR2APCPGAxitinibEAG9.7964e-030.2275image
chr3:48749537-48750463:-PCPGAxitinibEER1.5600e-030.2790image
ENSG00000114302.14,PRKAR2APRADBMS.536924EAG3.4566e-05-0.1906image
chr3:48749537-48750463:-PRADBMS.536924EER1.4184e-04-0.1761image
ENSG00000114302.14,PRKAR2AREADMG.132EAG9.5571e-03-0.2674image
chr3:48749537-48750463:-READBIRB.0796EER7.6770e-030.2763image
ENSG00000114302.14,PRKAR2ASARCBX.795EAG1.0868e-050.2957image
chr3:48749537-48750463:-SARCBX.795EER2.0268e-050.2882image
ENSG00000114302.14,PRKAR2ASKCMCEP.701EAG1.1661e-04-0.1843image
chr3:48749537-48750463:-SKCMCEP.701EER3.5224e-05-0.1979image
chr3:48749537-48750463:-STADAMG.706EER1.3660e-030.1663image
ENSG00000114302.14,PRKAR2ASTADAMG.706EAG1.4933e-030.1650image
chr3:48840242-48841068:-STADCHIR.99021EER1.8683e-020.4494image
chr3:48749537-48750463:-TGCTAZD6244EER5.7474e-03-0.2528image
ENSG00000114302.14,PRKAR2ATGCTAZD6244EAG2.7992e-02-0.2006image
chr3:48749537-48750463:-THCAAZD6482EER1.3328e-090.2788image
ENSG00000114302.14,PRKAR2ATHCAAZD6482EAG3.6763e-070.2352image
ENSG00000114302.14,PRKAR2ATHYMGemcitabineEAG1.1352e-02-0.3701image
chr3:48749537-48750463:-THYMBAY.61.3606EER1.3988e-02-0.3639image
ENSG00000114302.14,PRKAR2AUCECBleomycinEAG6.6990e-030.2323image
chr3:48749537-48750463:-UCECAxitinibEER1.1473e-030.2842image
ENSG00000114302.14,PRKAR2AUCSBortezomibEAG9.8096e-03-0.3896image
chr3:48749537-48750463:-UCSBortezomibEER7.9537e-03-0.3995image
ENSG00000114302.14,PRKAR2AUVMAG.014699EAG6.3360e-030.4010image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType